We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies. Cookie Policy.

LabMedica

Download Mobile App
Recent News Expo Clinical Chem. Molecular Diagnostics Hematology Immunology Microbiology Pathology Technology Industry Focus

NT-proBNP Underestimates Heart Failure Risk for Certain Patients

By LabMedica International staff writers
Posted on 03 May 2022

The N-terminal pro-B-type natriuretic peptides (NT-proBNP) concentration could mean drastically different absolute risks of heart failure (HF) for different demographics, according to a cohort study suggesting the importance of sex and race in interpreting risk for people free of HF at baseline.

N-terminal pro B-type natriuretic peptide (NT-proBNP) is an inactive peptide released along with the active peptide hormone BNP when the walls of the heart are stretched or there is pressure overload on the heart e.g. by fluid overload. BNP then acts on the kidneys causing fluid and sodium loss in the urine and mild vasodilation so releasing the pressure.


Image: N-terminal pro-B-type natriuretic peptides (NT-proBNP) concentration could mean drastically different absolute risks of heart failure (HF) for different demographics (Photo courtesy of TCTMD)
Image: N-terminal pro-B-type natriuretic peptides (NT-proBNP) concentration could mean drastically different absolute risks of heart failure (HF) for different demographics (Photo courtesy of TCTMD)

Cardiologists at the Brigham and Women’s Hospital (Boston, MA, USA) and their colleagues wanted to determine whether physiologic determinants of NT-proBNP concentrations account for sex and race differences, and to more uniformly predict HF risk using NT-proBNP in these demographic subgroups. The team enrolled 5,191 individuals from visit five averaged 76.0 ± 5.2 years of age. Men and Black people each accounted for 41% and 20%, respectively, of the overall cohort. The contribution of clinical, anthropometric, echocardiographic, and laboratory parameters to sex- and race-based differences in NT-proBNP concentration was assessed at visit five using linear regression. Participants included were free of HF in midlife.

The investigators reported that the median (IQR) NT-proBNP concentration was 124 (64-239) pg/mL. In both midlife and late life, NT-proBNP concentration was lowest in Black men (median [IQR] concentration: visit 2, 30 [14-67] pg/mL; visit five, 74 [34-153] pg/mL) and highest in White women (median [IQR] concentration: visit 2, 70 [42-111] pg/mL; visit, five, 154 [82-268] pg/mL). Substantial differences in the absolute risk of incident HF or death existed across the sex- and race-based categories at any NT-proBNP concentration (e.g., 7-fold [rate ratio, 6.7] and 3-fold [rate ratio, 2.7] difference at visit two and visit five, respectively, at guideline-recommended thresholds) with higher risk consistently observed among Black men and lower risk in White women.

The authors concluded that in their study, sex- and race-based differences in NT-proBNP persisted after accounting for known physiologic determinants. Absolute risk associated with a given value of NT-proBNP varied substantially by sex and race. Consideration of NT-proBNP values in the context of sex and race allows for more uniform prediction of absolute risk across important demographic subgroups. The study was published on April 27, 2022 in the journal JAMA Cardiology.

Related Links:
Brigham and Women’s Hospital


New
Gold Member
Chagas Disease Test
CHAGAS Cassette
New
Gold Member
Rotavirus Test
Rotavirus Test - 30003 – 30073
New
Celiac Disease Test
AESKULISA tTg-A New Generation
New
Urine Drug Test
Instant-view Propoxyphene Urine Drug Test

Latest Clinical Chem. News

Paper-Based Device Boosts HIV Test Accuracy from Dried Blood Samples

AI-Powered Raman Spectroscopy Method Enables Rapid Drug Detection in Blood

Novel LC-MS/MS Assay Detects Low Creatinine in Sweat and Saliva



Sekisui Diagnostics UK Ltd.